GlassScriptPhysician profile
Michael P Kehoe
NPI 1477870194
$3,354.55
in general payments reported to CMS, 2019-2025
19 companies · $1,168 in 2025
The $1,168 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $18.99 · 2021: $132 · 2022: $395 · 2023: $523 · 2024: $987 · 2025: $1,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,670 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,669.97 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,339.90 | 2019-2025 | |
| Genzyme Corporation | $327.65 | 2021-2025 | |
| Lilly USA, LLC | $202.87 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $196.83 | 2024-2025 | Dupixent |
| Amgen INC. | $186.78 | 2020-2024 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $186.12 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $154.18 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Novartis Pharmaceuticals Corporation | $136.31 | 2019-2025 | |
| Dermavant Sciences, INC. | $101.01 | 2023-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.17 | 2022-2025 | Spevigo |
| Incyte Corporation | $83.62 | 2024-2025 | Opzelura |
| Ucb, INC. | $66.97 | 2025 | Bimzelx |
| Celgene Corporation | $64.62 | 2019 | |
| Arcutis Biotherapeutics, INC. | $57.32 | 2023-2025 | Zoryve |
| Organon LLC | $44.52 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $43.16 | 2024-2025 | Nemluvio, Aklief |
| Pfizer INC. | $32.23 | 2022-2023 | |
| Leo Pharma INC. | $27.34 | 2025 | Adbry |
| Dusa Pharmaceuticals, INC. | $15.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kehoe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.